8GLS

Complex of human cystic fibrosis transmembrane conductance regulator (CFTR) and Z1834339853

8GLS の概要

• エントリーDOI: 10.2210/pdb8gls/pdb
• EMDBエントリー: 40207
• 分子名称: Cystic fibrosis transmembrane conductance regulator, human cystic fibrosis transmembrane conductance regulator, MAGNESIUM ION, ... (6 entities in total)
• 機能のキーワード: transporter, ion channel, transport protein
• 由来する生物種: Homo sapiens (human); 詳細
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 174975.94

構造登録者

Liu, F.,Chen, J. (登録日: 2023-03-23, 公開日: 2024-06-26, 最終更新日: 2025-01-08)

主引用文献

Liu, F.,Kaplan, A.L.,Levring, J.,Einsiedel, J.,Tiedt, S.,Distler, K.,Omattage, N.S.,Kondratov, I.S.,Moroz, Y.S.,Pietz, H.L.,Irwin, J.J.,Gmeiner, P.,Shoichet, B.K.,Chen, J.
Structure-based discovery of CFTR potentiators and inhibitors.
Cell, 187:3712-3725.e34, 2024

PubMed Abstract: The cystic fibrosis transmembrane conductance regulator (CFTR) is a crucial ion channel whose loss of function leads to cystic fibrosis, whereas its hyperactivation leads to secretory diarrhea. Small molecules that improve CFTR folding (correctors) or function (potentiators) are clinically available. However, the only potentiator, ivacaftor, has suboptimal pharmacokinetics and inhibitors have yet to be clinically developed. Here, we combine molecular docking, electrophysiology, cryo-EM, and medicinal chemistry to identify CFTR modulators. We docked ∼155 million molecules into the potentiator site on CFTR, synthesized 53 test ligands, and used structure-based optimization to identify candidate modulators. This approach uncovered mid-nanomolar potentiators, as well as inhibitors, that bind to the same allosteric site. These molecules represent potential leads for the development of more effective drugs for cystic fibrosis and secretory diarrhea, demonstrating the feasibility of large-scale docking for ion channel drug discovery.

PubMed: 38810646
DOI: 10.1016/j.cell.2024.04.046

実験手法

ELECTRON MICROSCOPY (3.8 Å)